Somewhat Positive Media Coverage Somewhat Unlikely to Impact Edwards Lifesciences Corporation (NYSE:EW) Stock Price
Media coverage about Edwards Lifesciences Corporation (NYSE:EW) has trended somewhat positive this week, according to Accern Sentiment. Accern identifies positive and negative news coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Edwards Lifesciences Corporation earned a coverage optimism score of 0.18 on Accern’s scale. Accern also assigned media headlines about the medical research company an impact score of 46.5387957822324 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
These are some of the news stories that may have effected Accern’s scoring:
- Penumbra (PEN) Loss Meets Estimates, Revenues Beat in Q2 (finance.yahoo.com)
- CVS Health (CVS) Q2 Earnings Beat, ’17 Guidance Narrowed – Yahoo Finance (finance.yahoo.com)
- Haemonetics (HAE) Q1 Earnings Beat, Revenues Miss Estimates – Yahoo Finance (finance.yahoo.com)
- CVS Health (CVS) Q2 Earnings Beat, ’17 Guidance Narrowed – Nasdaq (nasdaq.com)
- Edwards Lifesciences Corporation (EW) Receives Consensus Rating of “Buy” from Analysts (americanbankingnews.com)
Several equities research analysts recently commented on the company. Stifel Nicolaus reissued a “buy” rating and issued a $130.00 price target (up previously from $118.00) on shares of Edwards Lifesciences Corporation in a research note on Thursday, July 27th. Royal Bank Of Canada reaffirmed a “buy” rating and set a $130.00 target price on shares of Edwards Lifesciences Corporation in a research report on Friday, July 28th. Zacks Investment Research upgraded Edwards Lifesciences Corporation from a “hold” rating to a “buy” rating and set a $130.00 price target for the company in a report on Tuesday, July 18th. SunTrust Banks, Inc. upped their price target on Edwards Lifesciences Corporation to $14.00 and gave the stock a “buy” rating in a report on Monday, July 17th. Finally, Jefferies Group LLC upped their price target on Edwards Lifesciences Corporation from $115.00 to $132.00 and gave the stock a “buy” rating in a report on Thursday, July 27th. Five equities research analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. Edwards Lifesciences Corporation currently has an average rating of “Buy” and an average target price of $121.13.
Shares of Edwards Lifesciences Corporation (NYSE EW) opened at 116.26 on Thursday. Edwards Lifesciences Corporation has a 1-year low of $81.12 and a 1-year high of $121.75. The company has a market capitalization of $24.55 billion, a P/E ratio of 35.26 and a beta of 0.63. The company has a 50-day moving average price of $117.28 and a 200 day moving average price of $104.65.
Edwards Lifesciences Corporation (NYSE:EW) last announced its quarterly earnings data on Wednesday, July 26th. The medical research company reported $1.08 earnings per share for the quarter, beating the consensus estimate of $0.88 by $0.20. Edwards Lifesciences Corporation had a return on equity of 27.17% and a net margin of 22.16%. The business had revenue of $842 million during the quarter, compared to analyst estimates of $839.16 million. During the same period in the prior year, the company earned $0.76 earnings per share. Edwards Lifesciences Corporation’s revenue was up 10.9% compared to the same quarter last year. Equities research analysts anticipate that Edwards Lifesciences Corporation will post $3.78 EPS for the current year.
In other news, CEO Michael A. Mussallem sold 32,900 shares of the firm’s stock in a transaction on Monday, July 31st. The stock was sold at an average price of $114.80, for a total value of $3,776,920.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Donald E. Bobo, Jr. sold 25,000 shares of the firm’s stock in a transaction on Friday, August 4th. The stock was sold at an average price of $116.00, for a total value of $2,900,000.00. The disclosure for this sale can be found here. Insiders sold 150,512 shares of company stock valued at $17,360,159 over the last ninety days. Corporate insiders own 2.13% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Somewhat Positive Media Coverage Somewhat Unlikely to Impact Edwards Lifesciences Corporation (NYSE:EW) Stock Price” was originally published by Daily Political and is the property of of Daily Political. If you are reading this piece on another site, it was copied illegally and republished in violation of U.S. and international copyright laws. The correct version of this piece can be read at https://www.dailypolitical.com/2017/08/10/somewhat-positive-media-coverage-somewhat-unlikely-to-impact-edwards-lifesciences-corporation-nyseew-stock-price.html.
Edwards Lifesciences Corporation Company Profile
Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.
Receive News & Ratings for Edwards Lifesciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences Corporation and related companies with MarketBeat.com's FREE daily email newsletter.